Galderma v. Macleods Pharmaceuticals: ORACEA® Patent Dispute Dismissed in 48 Days
Galderma Laboratories and TCD Royalty Sub LP sued generic challenger Macleods Pharmaceuticals in Delaware over two doxycycline patents protecting ORACEA® 40 mg capsules. The parties reached an agreement within 48 days, resulting in a stipulated dismissal without prejudice — with Delaware retaining jurisdiction to enforce the deal.
ANDA Doxycycline Patent Dispute Resolved Before Litigation Gains Traction
On October 4, 2024, Galderma Laboratories, L.P. and royalty co-plaintiff TCD Royalty Sub LP filed an infringement action in the U.S. District Court for the District of Delaware against Macleods Pharmaceuticals Ltd. and its U.S. affiliate Macleods Pharma USA, Inc. The case concerned two patents — US7749532B2 and US8206740B2 — covering the modified-release doxycycline formulation marketed as ORACEA®, a 40 mg capsule used to treat rosacea. The lawsuit is consistent with the standard Hatch-Waxman ANDA litigation framework, in which a brand pharmaceutical company sues a generic challenger to trigger a 30-month stay.
The case closed just 48 days after filing, on November 21, 2024. Termination was effected via a Stipulation and Order of Dismissal Without Prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), tied to a private agreement between the parties dated November 1, 2024. Crucially, neither side bears costs or attorneys’ fees. The Delaware District Court explicitly retained jurisdiction to enforce and resolve disputes under that agreement — a provision typically associated with consent judgments or settlement-linked licensing arrangements.
A resolution in under seven weeks is notably swift for pharmaceutical patent litigation, suggesting the parties reached a commercial accommodation — likely a licensing or market-entry agreement — before substantive proceedings began. The without-prejudice dismissal, combined with court-retained jurisdiction, leaves the door open for enforcement if either party breaches the underlying deal. The specific financial or licensing terms are not disclosed in the public record, and the full competitive implications for ORACEA® market exclusivity remain unknown.
Filing to Dismissed without Prejudice in 48 days
48 days — well below the median ANDA patent trial timeline, suggesting early settlement or license
Dismissed without prejudice: what the stipulated order means for both parties
Rule 41 stipulated dismissal — what ‘without prejudice’ actually means
Under Fed. R. Civ. P. 41(a)(1)(A)(ii), both parties jointly filed a stipulation of dismissal — no court motion required. ‘Without prejudice’ is the critical qualifier: Galderma retains the legal right to refile the same infringement claims if the underlying agreement is breached or lapses. No merits determination was made. The court’s retained jurisdiction clause is unusual and signals the dismissal is tethered to an enforceable private agreement.
No merits rulingGalderma preserves enforcement rights while avoiding prolonged litigation
A without-prejudice dismissal is strategically favourable for the patent holder. Galderma and TCD Royalty Sub retain the ability to refile if Macleods launches at risk or breaches agreed terms. The court’s retained jurisdiction adds a fast-track enforcement mechanism without requiring a new complaint. Both patents remain presumptively valid — no invalidity finding was made. The outcome is consistent with a negotiated market-entry or licensing arrangement.
Patents intactMacleods avoids adverse judgment but faces ongoing patent exposure
Macleods Pharmaceuticals and its U.S. affiliate exit the litigation without a finding of infringement or invalidity. However, the without-prejudice dismissal means the patents have not been adjudicated — any future market entry outside agreed terms could trigger swift re-litigation. The parties’ November 2024 agreement likely sets conditions for any authorised generic launch or delayed entry. Macleods bears no legal costs under the stipulation.
No invalidity rulingCourt-retained jurisdiction signals a structured settlement, not a clean exit
Delaware courts retaining jurisdiction post-dismissal is a marker of agreements with ongoing obligations — most commonly patent licences, authorised generic deals, or negotiated entry dates. Competitors watching the ORACEA® generic landscape should note that Macleods’ path to market appears conditional. Other generic filers targeting the same doxycycline formulation should monitor whether the November 2024 agreement confers first-filer benefits or market exclusivity periods.
Structured resolution likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Galderma Laboratories | Individual | Pharmaceutical brand and royalty holder — co-owners of ORACEA® doxycycline 40 mg patentsSearch in Eureka ↗ |
| Co-Plaintiff | Tcd Royalty Sub, LP | Company | Search in Eureka ↗ |
| Defendant | Macleods Pharmaceuticals | Individual | India-based generic pharmaceutical manufacturer and its U.S. commercial subsidiarySearch in Eureka ↗ |
| Co-Defendant | Macleods Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Galderma LaboratoriesSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Galderma LaboratoriesSearch in Eureka ↗ |
| Presiding judge | Judge Stephanos Bibas | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is explicit in its scope: all claims, counterclaims, and affirmative defences asserted by both parties are dismissed without prejudice. The ‘without costs’ provision indicates neither party extracted a financial concession in the dismissal itself. Most significant is the retention-of-jurisdiction clause — Delaware courts do not retain jurisdiction as a formality; it indicates the November 2024 agreement contains enforceable obligations that may require judicial supervision. No infringement or invalidity determination was made, leaving both patents legally intact.
US7749532B2 & US8206740B2 — ORACEA® Doxycycline Modified-Release Formulation
US7749532B2 and US8206740B2 protect the modified-release doxycycline formulation at the heart of ORACEA®, a 40 mg capsule approved for reducing inflammatory lesions of rosacea. The patents cover the sub-antimicrobial dosing approach that distinguishes ORACEA® from conventional antibiotic doxycycline — a scientifically and commercially significant distinction. The application lineage traces to filings in the mid-2000s, reflecting innovation in the oral dermatological drug delivery space during a period of growing interest in anti-inflammatory, non-antibiotic dermatology therapeutics.
ORACEA® is one of the most commercially significant branded doxycycline products on the U.S. market. The two asserted patents effectively form a dual-layer exclusivity structure: one covering the formulation, the other covering methods of use — a common brand pharmaceutical strategy to extend lifecycle protection beyond a single patent. Generic challengers, including Macleods, must either design around both patents or successfully invalidate them at the PTAB or in district court. Neither has occurred here, leaving the patents strategically potent against future ANDA filers.
Should your doxycycline product run an FTO against US7749532B2 and US8206740B2?
Any company developing or commercialising a modified-release oral doxycycline formulation — particularly at or near 40 mg dosing — should treat these two patents as high-priority FTO targets. The combination of formulation and method-of-use claims creates overlapping coverage that is difficult to design around without clinical and regulatory risk. ANDA filers, generic manufacturers, and 505(b)(2) applicants in the doxycycline anti-inflammatory space face meaningful infringement exposure until these patents expire or are successfully challenged.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US7749532B2 and US8206740B2 against your product’s formulation parameters and intended indications — identifying freedom-to-operate gaps, relevant prior art for invalidity arguments, and expiry timelines across jurisdictions. Given the active royalty co-ownership structure involving TCD Royalty Sub LP, a full ownership and encumbrance review is also advisable before any licensing negotiation.
Run a freedom-to-operate analysis on US7749532B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Doxycycline & Branded Dermatology Patent Cases in Delaware
Explore related Hatch-Waxman infringement actions involving modified-release doxycycline and branded dermatology formulations litigated in Delaware District Court.
What this case signals for the ANDA pharmaceutical patent IP landscape
A 48-day resolution in Hatch-Waxman litigation is a strategic signal — not just a procedural footnote.
Sub-60-day ANDA dismissals almost always reflect a licensing or entry-date deal
Pharmaceutical patent suits filed under Hatch-Waxman rarely resolve on the merits in under 60 days. When they do close this quickly, the pattern is consistent with a negotiated authorised generic agreement, a delayed entry licence, or a settlement with market-access conditions. The Delaware court’s retained jurisdiction clause reinforces this read.
Without-prejudice dismissal preserves Galderma’s enforcement leverage
Brand pharmaceutical plaintiffs frequently prefer without-prejudice dismissals over consent judgments when the underlying agreement has ongoing performance conditions. This structure lets Galderma return to the same court — without refiling fees or delay — if Macleods breaches the November 2024 agreement. It functions as a built-in enforcement mechanism.
Laboratories v Macleods — key questions answered
Galderma and TCD Royalty Sub LP asserted two patents: US7749532B2 and US8206740B2. Both cover the modified-release doxycycline 40 mg formulation marketed as ORACEA®, a branded treatment for inflammatory rosacea lesions. The case was filed in Delaware District Court on October 4, 2024.
The case closed 48 days after filing, consistent with the parties reaching a private commercial agreement dated November 1, 2024. A without-prejudice dismissal under Rule 41(a)(1)(A)(ii) was then stipulated. The public record does not disclose the terms, but the speed and structure suggest a licensing or negotiated market-entry arrangement rather than a litigation win or loss on the merits.
A dismissal without prejudice means Galderma retains the right to refile the same infringement claims if Macleods breaches the November 2024 agreement or if new grounds arise. No court found the patents invalid or not infringed. The Delaware court’s retained jurisdiction means Galderma can seek enforcement of the agreement quickly without filing a new lawsuit.
TCD Royalty Sub LP is listed as a co-plaintiff alongside Galderma Laboratories, L.P., suggesting it holds a royalty interest or partial ownership stake in one or both of the asserted patents. Its presence indicates the patent rights have been monetised or encumbered through a royalty structure, which would require TCD’s standing to enforce the patents and its consent to any licensing resolution.
The public record does not reveal specific market-entry terms. However, the without-prejudice dismissal tied to a private agreement and the court’s retained jurisdiction strongly suggest Macleods’ entry into the doxycycline 40 mg market is subject to agreed conditions — potentially a delayed entry date or authorised generic arrangement. Other ANDA filers targeting ORACEA® should monitor any FDA Orange Book patent listing changes and Macleods’ regulatory status.
PatSnap Eureka searches patents and litigation data to answer instantly.